Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. Shares were up 29% to $8.81 in Monday afternoon ...
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravisPhase 2 TRITON trial of Descartes-08 in ...
Fintel reports that on March 9, 2026, Cantor Fitzgerald upgraded their outlook for Cartesian Therapeutics (NasdaqGM:RNAC) from Neutral to Overweight. Analyst Price Forecast Suggests 303.82% Upside As ...
Factorial Energy secures strategic investment to accelerate expansion into high-growth markets, including drones and mobile robotics.
The use of Cartesian and six-axis robots, as well as selective-compliance-articulated robot arms (SCARAs) is on the rise. They automate tasks to accelerate cycle times, increase throughput, and ...
Factorial’s high-power, lightweight, solid-state batteries have demonstrated real-world performance, including over 1,200 km (745 miles) of driving range in vehicle testing and are being advanced ...
Supposing you were in the market for a prototype of a circuit board here in 2013 – what kind of process would you have to go through to get one? Certainly one that'd require one whole heck of a lot ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results